Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kezar Life Sciences, Inc. Developing novel small molecule therapies for immune-mediated diseases and oncology.	United States of America	KZR
KNT-CT Holdings Co.,Ltd. A travel holding company offering themed tours and corporate travel solutions to boost Japan tourism.	Japan	9726
KoBioLabs, Inc. Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.	South Korea	348150
KOGI CORPORATION Engineering AI & IoT zero-touch hover interfaces for public kiosks and terminals.	Japan	5603
KOLON CORPORATION A holding company for diverse businesses in materials, chemicals, fashion, and life sciences.	South Korea	002020
kt nasmedia Co., Ltd. An integrated digital marketing platform for data-driven online, mobile, and OOH ad solutions.	South Korea	089600
Kubota Pharmaceutical Holdings Co., Ltd. Developing ophthalmic drugs and devices to preserve and restore vision for patients globally.	Japan	4596
Kweather Co., Ltd. Provider of weather data, air quality monitoring, and enterprise climate management solutions.	South Korea	068100
Kymera Therapeutics, Inc. Fintech firm providing data analytics and market intelligence for investment professionals.	United States of America	KYMR
LABCORP HOLDINGS INC. Provides diagnostic lab testing and biopharma drug development services for healthcare clients.	United States of America	LH